MLOps for Healthcare AI

Industry Application

MLOpsHealthcare

Healthcare is the highest-stakes domain for production AI—where model failures are measured not in revenue loss but in patient outcomes. MLOps has become foundational infrastructure for the healthcare industry precisely because clinical AI must meet a bar that no other sector demands: regulatory clearance, continuous audit trails, real-time explainability, and strict drift monitoring under HIPAA and FDA oversight. The FDA had authorized over 950 AI/ML-based Software as a Medical Device (SaMD) products by late 2024, and the operational discipline required to keep those systems safe, current, and compliant has made MLOps a board-level conversation at health systems, medtech companies, and life sciences firms alike.

Regulatory MLOps: The FDA's Predetermined Change Control Plan

The most consequential MLOps development specific to healthcare is the FDA's 2024 guidance on Predetermined Change Control Plans (PCCPs). Historically, any update to a cleared AI/ML medical device—even a routine retraining run—required a new 510(k) or De Novo submission, making continuous training pipelines effectively illegal. PCCPs allow manufacturers to define, in advance, what types of model updates (retraining on new data, performance threshold adjustments, input feature modifications) are permissible without triggering a new regulatory submission, provided the changes fall within pre-specified bounds. This has directly shaped MLOps architecture at companies like Aidoc, Viz.ai, and Tempus AI: their CI/CD/CT pipelines now encode PCCP boundaries as hard constraints, with automated gates that halt deployment if a candidate model's behavioral delta exceeds the FDA-filed specification. The result is a novel form of Continuous Training that is simultaneously a regulatory document and a software artifact.

Clinical Model Drift and the Monitoring Imperative

Healthcare datasets are uniquely susceptible to distributional shift. A sepsis prediction model trained on pre-pandemic ICU data performs materially differently post-COVID, not because the underlying biology changed, but because care protocols, comorbidity profiles, and patient demographics shifted. A 2023 study in Nature Medicine found that 40% of clinical AI models showed statistically significant performance degradation within 18 months of deployment without active monitoring. This has made model monitoring and data drift detection central to healthcare MLOps stacks. Epic Systems—whose Cognitive Computing platform now runs AI models for over 300 health systems—has integrated drift alerting directly into its AI governance dashboard, flagging models whose AUC or calibration shifts beyond a configurable threshold and surfacing alerts to both clinical informaticists and the AI vendor responsible for the model.

EHR Integration and the HL7 FHIR Layer

Healthcare MLOps cannot be separated from the EHR ecosystem. The shift to HL7 FHIR (Fast Healthcare Interoperability Resources) as the dominant data exchange standard has created a new integration surface for ML pipelines. Feature stores in healthcare settings increasingly ingest FHIR R4 resources—Observations, Conditions, MedicationRequests—and normalize them into consistent feature representations that survive EHR vendor changes. Microsoft Azure Health Data Services (formerly Azure API for FHIR) and AWS HealthLake both provide managed FHIR-native data stores with built-in ML integration. Flatiron Health, the Roche-owned oncology data platform, operates one of the most sophisticated healthcare feature pipelines in the industry, curating structured clinical data from over 280 community oncology practices and feeding it into models used for real-world evidence generation and clinical trial matching. Their MLOps stack handles the versioning of both features and oncology-specific ontologies (ICD-10, RxNorm, SNOMED CT) as first-class artifacts—a requirement that general-purpose feature store platforms are only beginning to address natively.

Medical Imaging AI: From Research to Production at Scale

Radiology and pathology represent the most mature deployment surface for healthcare AI, and consequently the most mature healthcare MLOps practices. Aidoc, which operates AI triage and prioritization tools across over 1,000 hospital radiology departments globally, runs what is effectively a multi-tenant MLOps platform: each customer's PACS (Picture Archiving and Communication System) integration produces a distinct data stream, and models must be monitored per-site for performance variance caused by scanner manufacturer differences, imaging protocol variation, and patient population heterogeneity. Aidoc's operational model treats per-hospital model calibration as a standard MLOps workflow, not an exception. PathAI, which deploys deep learning models for digital pathology—including FDA-cleared tools for breast cancer grading—faces analogous challenges with staining variation across pathology labs, and has invested heavily in domain adaptation pipelines that sit between raw whole-slide image ingestion and model inference. Rad AI's ambient reporting platform uses LLM-based LLMOps infrastructure layered on top of traditional imaging model pipelines, combining structured radiology findings with generative report drafting—an early production example of hybrid MLOps/LLMOps architecture in a regulated clinical context.

Drug Discovery and Genomics: Batch MLOps at Scale

Life sciences MLOps operates on longer iteration cycles than clinical AI but at enormous computational scale. Recursion Pharmaceuticals runs one of the largest biological foundation models in production, trained on petabytes of cellular imaging data. Their MLOps infrastructure—built on a combination of Kubernetes, MLflow for experiment tracking, and custom data versioning—manages model lineage across experiments that span months and datasets that cannot be regenerated. Insilico Medicine deployed an AI-designed drug candidate (ISM001-055 for IPF) into Phase II trials as of 2024, with their generative chemistry models operating under MLOps governance that satisfies both FDA IND requirements and internal scientific reproducibility standards. Tempus AI, which went public in 2024, operates a genomic data platform that feeds ML models for treatment response prediction across oncology, neurology, and cardiology—with MLOps pipelines designed to handle the regulatory separation between their CLIA-certified laboratory operations and their AI model serving infrastructure.

Applications & Use Cases

Clinical Decision Support Monitoring

Health systems like Mayo Clinic and Mass General Brigham deploy real-time sepsis, deterioration, and readmission risk models that require continuous performance monitoring. MLOps pipelines track prediction calibration against actual outcomes, triggering automated retraining when Brier scores degrade beyond acceptable thresholds—without manual intervention from data science teams.

Radiology AI Triage Pipelines

Companies like Aidoc and Viz.ai run multi-tenant model serving infrastructure across thousands of hospital PACS integrations. Each site receives model inference with per-hospital performance telemetry, and MLOps tooling manages the versioning and rollout of updated models across heterogeneous imaging environments—often constrained by PCCP boundaries filed with the FDA.

Genomic Pipeline Versioning

Precision oncology platforms (Tempus AI, Foundation Medicine, Guardant Health) manage complex ML pipelines that process ctDNA and tumor sequencing data. MLOps governs model versioning across CLIA-compliant laboratory workflows, ensuring that clinical reports generated from the same sample are reproducible under audit and that model updates are traceable to specific regulatory submissions.

Drug Discovery Model Lifecycle

Recursion Pharmaceuticals and BenevolentAI run continuous training pipelines for molecular property prediction and target identification. MLOps infrastructure tracks experiment provenance from raw assay data through feature engineering to model artifacts, satisfying both internal reproducibility requirements and the documentation standards expected in IND filings with regulators.

Ambient Clinical Documentation

Microsoft's Nuance DAX and similar ambient AI platforms transcribe and structure clinical encounters in real time using LLM-based pipelines. Healthcare LLMOps here involves prompt versioning, per-specialty fine-tune management, and hallucination monitoring against structured clinical data—ensuring that AI-generated SOAP notes meet documentation accuracy standards before surfacing to physicians.

Payer Risk Stratification

Health insurance payers (UnitedHealth's Optum, Humana) operate large-scale member risk models for chronic disease management outreach and prior authorization support. MLOps pipelines manage monthly retraining cycles on claims data, with feature drift monitoring to detect coding practice changes that corrupt model inputs before they propagate to downstream care management decisions.

Key Players

Epic Systems — The dominant EHR vendor has embedded AI governance and model monitoring directly into its platform. Epic's Cognitive Computing suite allows third-party AI vendors to deploy models into clinical workflows with drift alerting and usage telemetry natively integrated—effectively functioning as a managed MLOps runtime for the US hospital market.
Aidoc — Operates a radiology AI platform across 1,000+ hospitals with a purpose-built multi-tenant MLOps stack. Their aiOS platform manages model lifecycle, per-site performance monitoring, and PCCP-compliant update pipelines across a portfolio of FDA-cleared imaging AI tools.
Microsoft (Nuance + Azure Health) — Through the Nuance acquisition and Azure Health Data Services, Microsoft provides both an LLMOps-powered ambient documentation product (DAX Copilot) and the underlying cloud infrastructure (Azure Machine Learning, Azure Health Data Services) that many healthcare AI vendors use for model training and deployment.
Tempus AI — Publicly traded genomics and clinical AI platform that operates one of the most sophisticated healthcare feature pipelines in oncology. Their MLOps infrastructure bridges CLIA laboratory workflows and AI model serving while maintaining regulatory separation required by FDA and CMS.
Recursion Pharmaceuticals — Drug discovery company running biological foundation models on petabyte-scale cellular imaging datasets. Their MLOps infrastructure is among the most computationally intensive in life sciences, managing model provenance across multi-month experimental cycles.
PathAI — Digital pathology AI company with FDA-cleared tools for cancer grading. Operates domain adaptation and staining normalization pipelines as core MLOps infrastructure, enabling models trained on one lab's slides to perform consistently across pathology labs with different preparation protocols.
Optum (UnitedHealth Group) — Operates healthcare AI at the largest scale in the US insurance market, with MLOps pipelines managing risk stratification, prior authorization, and care management models across hundreds of millions of member-months of claims data annually.

Challenges & Considerations

FDA Regulatory Compliance — Every production model update to an FDA-cleared SaMD potentially constitutes a device modification requiring new regulatory submission. Building MLOps pipelines that encode PCCP boundaries as automated deployment gates—and maintaining the documentation trail required for FDA audit—adds substantial engineering overhead that general-purpose MLOps platforms do not address out of the box.
HIPAA and PHI in Training Pipelines — Protected Health Information cannot flow freely through standard cloud-based MLOps infrastructure. Healthcare organizations must either implement on-premises or VPC-isolated training environments, use HIPAA Business Associate Agreement-covered cloud services, or employ federated learning approaches—all of which constrain the tooling choices available and increase infrastructure complexity.
Multi-Site Model Variance — Clinical AI models frequently exhibit significant performance variation across hospital sites due to differences in patient demographics, care protocols, EHR configuration, and imaging equipment. MLOps pipelines must support per-site monitoring, site-specific calibration, and selective retraining in ways that general-purpose platforms were not designed for.
Explainability Requirements — Clinicians and regulators increasingly require that AI predictions be accompanied by human-interpretable rationale. Integrating explainability frameworks (SHAP, LIME, attention visualization for imaging models) into production inference pipelines adds latency and complexity, and maintaining explanation consistency across model versions requires versioning explainability artifacts alongside model weights.
Data Scarcity and Label Quality — Ground truth labels in healthcare often require expert clinical annotation, are expensive to obtain, and may reflect historical diagnostic practices that are themselves inconsistent. MLOps pipelines must incorporate active learning, label quality monitoring, and annotation versioning workflows that are rare in non-healthcare ML systems.
Interoperability Fragmentation — Despite FHIR adoption, healthcare data remains fragmented across EHR vendors (Epic, Oracle Health, Meditech), proprietary lab systems, imaging archives, and claims databases. Building and maintaining the data ingestion layer for healthcare MLOps pipelines is often more complex than the model development itself, and changes in upstream EHR configuration can silently corrupt feature pipelines without triggering obvious alerts.